Clinical trial Recruiting at 1 site Phase 4 Interventional Ages 18 and up

Intranasal sphenopalatine ganglion block for headache after a ruptured brain aneurysm

Official title: Intranasal Sphenopalatine Ganglion Blockade as a Non-invasive, Opioid-sparing Treatment for Headaches Following Aneurysmal Subarachnoid Hemorrhage

Run by Wright State University · NCT07116408 · Data updated 2026-11-12

This will test whether spraying a numbing medicine into the back of the nose can reduce severe headache in adults recovering from a ruptured brain aneurysm.

More Headache trials

Quick facts

PhasePhase 4
Study typeInterventional
Ages18 Years and up
SexAll
Enrollment20 (estimated)
SponsorWright State University
Academic / other
Locations1 site (Dayton, Ohio)
StatusRecruiting
StartedMay 20, 2024
Main results expectedNovember 2026
Study endsMay 2027
Registry record updatedMay 27, 2026
Trial IDNCT07116408 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults (18+) treated for aneurysmal subarachnoid hemorrhage in the neuro ICU who have Hunt and Hess scores of 0–3, can verbally report headache, and can consent are ideal candidates.

Probably not a fit

Patients with Hunt and Hess scores of 4–5, lidocaine allergy, pregnancy, certain nasal or bleeding contraindications, inability to consent, prisoners, or other excluded vulnerable groups are not eligible and unlikely to benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional Phase 4 trial tests an intranasal sphenopalatine ganglion (SPG) block using lidocaine delivered via the Tx 360 device to treat headache after aneurysmal subarachnoid hemorrhage. All participants continue to receive standard pain medicines as needed while investigators record pain scores and side effects. The SPG block targets a nerve bundle linked to head pain and has shown benefit in other headache disorders and in a small pilot for SAH-related pain. The goal is to reduce headache intensity and opioid-related side effects without adding new adverse effects.

Why it matters

Potential benefit: If successful, this approach could lessen severe headache and reduce the need for opioid pain medicines, lowering sedation and breathing-related side effects.

How similar studies have gone: Small pilot data and successful use of SPG blockade in cluster and other headache disorders suggest promise, but large randomized evidence specifically for aSAH headaches is lacking.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

• Patients aged 18 years or older who are being treated in the neurologic ICU for subarachnoid hemorrhage with Hunt and Hess scale of 0-3 (Scale ranges from 0 to 5 with higher numbers indicating more severe symptoms) and able to verbally report headache will be considered for inclusion in this study.

Exclusion Criteria:

* Patients under the age of 18 years of age.
* Patients with an allergy to lidocaine.
* Patients from all vulnerable groups.
* Patients with Hunt and Hess scale score of 4-5. (Scale ranges from 0 to 5 with higher numbers indicating more severe symptoms.)
* Patients who are not able to consent.
* Mentally impaired patients that are unable to provide consent.
* Patients that are prisoners.
* Pregnant patients.

Additionally, patients with contraindications to use of the Tx 360 device will be excluded. Contraindications include:

* History of recurrent nose bleeds.
* Nasal septal deformity such as cleft lip and palate, choanal atresia (narrowed nasal passages), atrophic rhinitis, rhinitis medicamentosa, septal perforation, nasal/midface trauma.
* Recent nasal/sinus surgery
* Presence of a bleeding disorder (eg., Von Willebrand's disease or hemophilia).
* Severe respiratory distress.
* Presence of angiofibroma, sinus tumor, or granulomatous disease of the nasopharynx.
* Presence of nasal trauma.
* Nasal congestion that has been present more than 10 days, high fever, or abnormal appearance of the nasal mucosa or mucus.

Where it's running

  • Miami Valley Hospital
    Dayton, Ohio, United States
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.